Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Tamsulosin and Mirabegron in Healthy Males
NCT04485585Phase 1Completed
- Sponsor
- Boryung
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tamsulosin and mirabegron in benign prostatic hyperplasia (BPH) and overactive bladder (OAB), sponsored by Boryung. Primary endpoints: Maximum steady-state plasma drug concentration and Area under the plasma concentration-time curve. Started Jul 2020; status: completed.
02
Drugs
tamsulosinmirabegron
03
Conditions
benign prostatic hyperplasia (BPH)overactive bladder (OAB)
Beyond the preview
Go deeper on NCT04485585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485585.